skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Medical databases in studies of drug teratogenicity: methodological issues

Review

(2440) Views  (697) Full article downloads

Authors: Vera Ehrenstein, Henrik T Sørensen, Leiv S Bakketeig, et al

Published Date March 2010 Volume 2010:2 Pages 37 - 43
DOI: http://dx.doi.org/10.2147/CLEP.S9304

Vera Ehrenstein1, Henrik T Sørensen1, Leiv S Bakketeig1,2, Lars Pedersen1

1Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; 2Norwegian Institute of Public Health, Oslo, Norway

Abstract: More than half of all pregnant women take prescription medications, raising concerns about fetal safety. Medical databases routinely collecting data from large populations are potentially valuable resources for cohort studies addressing teratogenicity of drugs. These include electronic medical records, administrative databases, population health registries, and teratogenicity information services. Medical databases allow estimation of prevalences of birth defects with enhanced precision, but systematic error remains a potentially serious problem. In this review, we first provide a brief description of types of North American and European medical databases suitable for studying teratogenicity of drugs and then discuss manifestation of systematic errors in teratogenicity studies based on such databases. Selection bias stems primarily from the inability to ascertain all reproductive outcomes. Information bias (misclassification) may be caused by paucity of recorded clinical details or incomplete documentation of medication use. Confounding, particularly confounding by indication, can rarely be ruled out. Bias that either masks teratogenicity or creates false appearance thereof, may have adverse consequences for the health of the child and the mother. Biases should be quantified and their potential impact on the study results should be assessed. Both theory and software are available for such estimation. Provided that methodological problems are understood and effectively handled, computerized medical databases are a valuable source of data for studies of teratogenicity of drugs.

Keywords: databases, birth defects, epidemiologic methods, pharmacoepidemiology






 

Other articles by Dr Vera Ehrenstein



Readers of this article also read:

30-days mortality in patients with perforated peptic ulcer: A national audit
Potential misinterpretations caused by collapsing upper categories of comorbidity indices: An illustration from a cohort of older breast cancer survivors
Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer
Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis
Medical complications in patients with stroke: data validity in a stroke registry and a hospital discharge registry
Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank
National Stroke Audit: The Australian experience
Existing data sources for clinical epidemiology: Aarhus University Prescription Database
Existing data sources for clinical epidemiology: The clinical laboratory information system (LABKA) research database at Aarhus University, Denmark
Stability of additive treatment effects in multiple treatment comparison meta-analysis: a simulation study